Editorial Board About Us

Victor W Nitti

All articles from this author are listed below.

Volume 7, Supplement 6 Review Articles

Measurement of Bladder Mass Using Ultrasonography: A New Tool for Measuring Bladder Outlet Obstruction

Volume 7, Supplement 6 Review Articles

Pressure Flow Urodynamic Studies: The Gold Standard for Diagnosing Bladder Outlet Obstruction

Lower urinary tract symptoms Bladder outletobstruction Postvoid residual urine volume Urodynamic studies Detrusor contractility

Volume 7, Supplement 8 Review Articles

Primary Bladder Neck Obstruction in Men and Women

Primary bladder neck obstruction Blockers Videourodynamics Voiding

Volume 7, Supplement 4 Review Articles

Is There a Role for a-Blockers for the Treatment of Voiding Dysfunction Unrelated to Benign Prostatic Hyperplasia?

Benign prostatic hyperplasia Lower urinary tract symptoms Alpha-adrenore-

Volume 8, Number 4 Review Articles

Botulinum Toxin for the Treatment of Idiopathic and Neurogenic Overactive Bladder: State of the Art

Treatment Update

The pharmacologic treatment of overactive bladder and detrusor overactivity, whether idiopathic or neurogenic, has centered around blocking muscarinic receptors on the detrusor muscle. Although newer agents have been developed with better tolerability and safety, the basic mechanism by which the “irritable” detrusor is treated has not changed in decades. Although effective in many cases of idiopathic and neurogenic detrusor overactivity and overactive bladder, antimuscarinic agents fall short in many other cases because of lack of efficacy and/or tolerability. For the past several years, there has been increasing evidence to support the use of botulinum toxin for the treatment of detrusor overactivity and overactive bladder syndrome not effectively treated by anticholinergics. From early open-label studies to the more recent randomized, controlled trials, efficacy and tolerability data have been very encouraging. Botulinum toxin is not yet approved by the US Food and Drug Administration for the treatment of detrusor overactivity and overactive bladder, but the positive results seen thus far cannot be ignored. [Rev Urol. 2006;8(4):198-208]

Botulinum toxin Detrusor overactivity Antimuscarinic agents

Volume 8, Number 3 Meeting Reviews

Best of the 2006 AUA Annual Meeting

Meeting Review

Shachi Tyagi Li-Ming Su Michael E Aldridge Tobias Klatte John P Mulhall John P Stein Arie S Belldegrun Michael K Brawer Claus G Roehrborn Jacob Rajfer J Curtis Nickel Danil V Makarov Victor W Nitti Michael B Chancellor Alan W Partin Ellen Shapiro

Highlights from the 2006 Annual Meeting of the American Urological Association May 20–25, 2006 Atlanta, GA

Prostate cancer Infertility Benign prostatic hyperplasia Bladder cancer Kidney cancer Lower urinary tract symptoms Bladder exstrophy Overactive bladder Interstitial cystitis Stress urinary incontinence Peyronie’s disease Spina bifida Neurogenic bladder Erectile dysfunction Chronic pelvic pain syndrome Chronic prostatitis Tumor markers Androgen replacement therapy Ejaculatory dysfunction Anorectal malformations Renal stones Robotic-assisted radical prostatectomy

Volume 10, Number 3 Meeting Reviews

Urodynamics, Incontinence, and Neurourology

Meeting Review

Highlights from the Society for Urodynamics and Female Urology Annual Winter Meeting, February 28-March 2, 2008, Miami, FL [Rev Urol. 2008;10(3):229-231]

Urodynamics Interstitial cystitis Stress incontinence Pelvic organ prolapse Painful bladder syndrome Neurourology Neuromodulation

Volume 11, Number 4 Review Articles

Defining Efficacy in the Treatment of Overactive Bladder Syndrome

Management Update

Sagar Shah Victor W Nitti

Patients seek treatment for overactive bladder syndrome (OAB) due to poor quality of life, and perceived improvement in quality of life (QOL) from medical therapy is multifactorial. Many feel that efficacy/success of medical therapy for OAB should not be linked to improvements in 1 or 2 endpoints, but instead should be linked to patient expectation and QOL improvement. Ideally, once patient-centered goals are defined, outcomes should be correlated with relief of symptom(s), patient satisfaction, and goal attainment expectations as a result of treatment.[Rev Urol. 2009;11(4):196-202 doi: 10.3909/riu0480]© 2009 MedReviews®, LLC

Medical therapy Overactive bladder syndrome Patient-centered treatment

Volume 15, Number 2 Review Articles

Management of Recurrent Urinary Tract Infections in Healthy Adult Women

Management Update

Duane R Hickling Victor W Nitti

Recurrence after urinary tract infection (rUTI) is common in adult women. The majority of recurrences are believed to be reinfection from extraurinary sources such as the rectum or vagina. However, uropathogenic Escherichia coli are now known to invade urothelial cells and form quiescent intracellular bacterial reservoirs. Management of women with frequent symptomatic rUTI can be particularly vexing for both patients and their treating physicians. This review addresses available and promising management strategies for rUTI in healthy adult women. [Rev Urol. 2013;15(2):41-48 doi: 10.3909/riu0566] © 2013 MedReviews®, LLC

Recurrent urinary tract infection Uropathogenic Escherichia coli Prophylaxis

Volume 19, Number 3 NYU Case of the Month

Midurethral Sling Erosion

August 2017

[Rev Urol. 2017;19(3):185–186 doi: 10.3909/riu0773] © 2017 MedReviews®, LLC